Becton Dickinson
BDX
$170.66
+0.32%
Becton, Dickinson and Co. (BDX) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products across four business units: Medical Essentials, Connected Care, Biopharma Systems, and Interventional. As a diversified player in the healthcare industry, BDX holds a strong market position with a broad portfolio of essential products, including syringes, infusion pumps, and prefillable syringes, serving hospitals, clinics, and pharmaceutical manufacturers. The current investor narrative centers on the company's recent operational performance, highlighted by a Q2 earnings beat and a raised full-year profit outlook, yet tempered by skepticism from some analysts regarding sustainability and growth prospects. Additionally, the stock has experienced significant volatility, including a sharp drop in early 2026, prompting debates about the company's turnaround strategy and long-term growth trajectory.…
BDX
Becton Dickinson
$170.66
Related headlines
Investment Opinion: Should I buy BDX Today?
Based on the analysis, BDX is rated a Hold. The consensus is Buy with an average target of $180.25, implying 8.8% upside, but the recent revenue decline and net loss temper enthusiasm. The thesis is that BDX is a value play with a strong franchise, but it needs to demonstrate consistent growth and margin recovery to justify a higher multiple.
Sign up to view all
BDX 12-Month Price Forecast
The AI assessment is neutral, reflecting the mixed signals. The valuation is attractive, but the recent revenue decline and net loss are concerning. The market's expectation of a strong earnings rebound is reflected in the forward P/E, but this is not yet visible in the trailing numbers. The stance would upgrade to bullish if revenue growth turns positive and margins expand, or downgrade to bearish if the company misses earnings again.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $180.25 and implied upside of +5.6% versus the current price.
Average Target
$180.25
0 analysts
Implied Upside
+5.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$161 - $225
Analyst target range
BDX is covered by 12 analysts, with a consensus recommendation of 'Buy' (mean rating of 2.07 on a scale where 1 is Strong Buy and 5 is Sell). The average target price is $180.25, implying an upside of approximately 8.8% from the current price of $165.62. The distribution of ratings is not explicitly provided, but the consensus leans bullish, with recent actions from firms like Evercore ISI (Outperform), Barclays (Overweight), and Citigroup (Buy) indicating positive sentiment. The target price range spans from a low of $161.00 to a high of $225.00, with the high target suggesting potential for significant upside if the company executes on its growth initiatives and improves profitability, while the low target reflects concerns about continued revenue declines and margin pressure. The relatively wide spread between the low and high targets (64 points) indicates moderate uncertainty among analysts regarding BDX's future performance. Recent institutional ratings show no major downgrades, with most firms maintaining their previous stances, suggesting stability in analyst sentiment. Overall, the consensus is moderately bullish, but the modest upside to the average target implies that the stock is not seen as deeply undervalued, and investors should monitor the company's ability to sustain its recovery.
Bulls vs Bears: BDX Investment Factors
BDX presents a mixed picture: the stock is deeply undervalued relative to its history, with a forward P/E of 12.3x and a P/S of 1.93x, and analysts are moderately bullish with a Buy consensus. However, the recent revenue decline and net loss highlight operational challenges that could undermine the recovery. The bull case rests on margin improvement and cost discipline, while the bear case hinges on continued top-line weakness and debt burden. Currently, the bearish evidence is slightly stronger due to the negative revenue trend and earnings miss, but the valuation discount and analyst support provide a floor. The key tension is whether the Q2 beat marks a turning point or a temporary reprieve; if revenue growth resumes and margins expand, the stock could re-rate significantly, but if not, it may remain range-bound.
Bullish
- Q2 Beat and Raised Profit Outlook: BDX delivered a strong Q2 FY2026 beat and raised its full-year profit outlook, signaling operational resilience despite a 10.6% revenue decline. This suggests management's confidence in margin recovery and cost discipline, which could support earnings growth.
- Attractive Valuation vs. History: The stock trades at a P/S ratio of 1.93x, well below its historical range of 7x-12x over the past five years, and a forward P/E of 12.30x. This deep discount may offer a margin of safety if the company's turnaround gains traction.
- Analyst Consensus is Buy: With a mean rating of 2.07 (Buy) and an average target price of $180.25, analysts see ~8.8% upside. Recent actions from Evercore ISI, Barclays, and Citigroup are positive, indicating institutional confidence in the company's direction.
- Strong Free Cash Flow Generation: BDX generated $3.14 billion in trailing twelve-month free cash flow, providing ample liquidity to service debt, fund dividends, and invest in growth initiatives. This cash generation supports the current dividend yield of 2.84%.
Bearish
- Revenue Decline in Q2 FY2026: Q2 FY2026 revenue fell 10.6% YoY to $4.714 billion, following a 5.2% increase in Q1. This volatility raises concerns about demand sustainability and market share, especially in the Medical and Life Sciences segments.
- Net Loss and Negative EPS: BDX reported a net loss of -$311 million and EPS of -$1.11 in Q2 FY2026, driven by a sharp drop in operating income to $94 million. This indicates significant margin pressure and operational challenges that could persist.
- Underperformance vs. Market: The stock is down 7.09% over the past year, while the S&P 500 gained 18.19%. Relative strength is negative across all timeframes, with a 1-year relative strength of -25.28%, suggesting persistent selling pressure and weak investor sentiment.
- High Debt Levels: Debt-to-equity ratio stands at 0.755, and interest expense was $149 million in Q2 FY2026, up from $107 million in Q1. High leverage increases financial risk, especially if revenue growth remains sluggish.
BDX Technical Analysis
BDX's price trend over the past year has been predominantly downward, with a 1-year price change of -7.09%, underperforming the S&P 500's +18.19% gain. The stock is currently trading at $165.62, which is approximately 88% of its 52-week range (low of $127.59, high of $187.35), indicating it is closer to the lower end of its annual range. This positioning suggests that the stock has been in a sustained downtrend, with the current price reflecting a significant recovery from the lows but still well below the highs, implying a potential value opportunity or a falling knife scenario depending on fundamental support.
Beta
0.26
0.26x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$128-$187
Price range past year
Annual Return
-3.5%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | +9.7% | +2.5% |
| 3m | +11.4% | +5.2% |
| 6m | -18.7% | +11.5% |
| 1y | -3.5% | +22.6% |
| ytd | -12.5% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
BDX's revenue trajectory has been volatile, with the most recent quarter (Q2 FY2026, ending March 31, 2026) reporting revenue of $4.714 billion, a 10.6% decline year-over-year, following a 5.2% increase in Q1 FY2026. The multi-quarter trend shows mixed results: Q4 FY2025 revenue grew 8.3% YoY, Q3 FY2025 grew 10.4%, but Q2 FY2025 declined 10.6% YoY, indicating inconsistent growth. The company's revenue segments show Medical at $2.4 billion and Life Sciences at $2.5 billion, with Life Sciences slightly larger, but both segments appear to be facing headwinds. This deceleration in revenue growth raises concerns about the company's ability to sustain top-line expansion, though the recent Q2 beat and raised profit outlook suggest some operational resilience.
Quarterly Revenue
$4.7B
2026-03
Revenue YoY Growth
-10.6%
YoY Comparison
Gross Margin
45.7%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
Given that BDX reported a net loss of -$311 million in the most recent quarter, the trailing P/E ratio is not meaningful, so I selected the price-to-sales (P/S) ratio as the primary valuation metric. The current P/S ratio is 1.93x, based on trailing twelve-month sales, while the forward P/E is 12.30x, indicating that the market expects earnings to recover significantly. The gap between the trailing P/E (negative) and forward P/E suggests that analysts anticipate a strong earnings rebound, which is a positive signal if realized. Compared to the industry average P/S ratio (not provided, but typically around 3-4x for medical instruments), BDX's P/S of 1.93x appears to be at a discount, potentially reflecting the company's recent earnings struggles and lower growth expectations. Historically, BDX's P/S ratio has ranged from approximately 7x to 12x over the past five years, with the current 1.93x well below the historical range, indicating that the stock is trading at a significant discount to its own valuation history, which could signal either a value opportunity or a deterioration in fundamentals.
PE
25.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~55x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant: BDX's Q2 FY2026 net loss of -$311 million and negative EPS of -$1.11 highlight earnings volatility, while operating margin compressed to just 2.0% from 11.3% in Q1. The company carries a debt-to-equity ratio of 0.755, with interest expense rising to $149 million, and a current ratio of 1.11, indicating tight liquidity. Free cash flow of $3.14 billion provides some cushion, but continued losses could strain the balance sheet and limit investment capacity.
FAQ
The key risks include: 1) Financial risk: high debt (D/E of 0.755) and a net loss in Q2 FY2026, which could strain liquidity. 2) Operational risk: revenue decline of 10.6% YoY, indicating demand weakness. 3) Competitive risk: intense competition in medical devices could erode market share. 4) Macro risk: healthcare policy changes and economic downturns could impact demand. The most severe risk is a continued deterioration in fundamentals, which could push the stock to its 52-week low of $127.59, a -23% downside.
The 12-month forecast is mixed. In the base case (50% probability), the stock trades around $180, in line with the average analyst target. In the bull case (25% probability), it could reach $225, driven by successful execution. In the bear case (25% probability), it could fall to $128, near the 52-week low. The most likely scenario is the base case, assuming revenue stabilizes and margins recover. The key assumption is that the Q2 beat is a turning point, not a one-off.
BDX is undervalued relative to its own history, with a P/S ratio of 1.93x versus a 5-year range of 7-12x, and a forward P/E of 12.3x, which is below the market average. Compared to peers, the P/S is also at a discount, suggesting the market is pricing in lower growth and margin pressure. The valuation implies that investors expect a significant earnings recovery, as the trailing P/E is negative. If the company can deliver on its profit outlook, the stock is cheap; if not, the low valuation may be justified.
BDX offers a compelling risk/reward at current levels, with a forward P/E of 12.3x and a P/S of 1.93x, both below historical averages. Analysts see an 8.8% upside to the average target of $180.25, and the dividend yield of 2.84% provides income. However, the recent revenue decline and net loss are red flags. For long-term investors with a tolerance for volatility, BDX could be a good buy, but it is not without risk. If you believe the turnaround will succeed, the stock is undervalued; otherwise, it may be a value trap.
BDX is better suited for long-term investment, given its low beta of 0.271 and dividend yield of 2.84%, which provide stability. The stock is in a turnaround phase, and short-term trading is risky due to earnings volatility and negative momentum. A minimum holding period of 3-5 years is recommended to allow the company to execute its strategy and for the market to recognize the value. For short-term traders, the stock may offer opportunities around earnings, but the risk is elevated.